HIV escape in the central nervous system (CNS) despite undetectable viral load in the plasma has been observed and may contribute to HIV-associated neurocognitive disorders. Favouring the use of HIV drugs with a good penetration into the CNS has been advocated, leading to the establishment of the CNS penetration-effectiveness (CPE) score. However, the relevance of this score is not fully established. Ciccarelli et al. compared two versions of the CPE scores in their capacity to predict cognitive dysfunction in HIV-infected individuals. The revised CPE score, but not the original one, showed an improved association with cognitive impairment. Prospective studies are warranted to assess the validity of the CPE score.
References
1.
AntinoriA., ArendtG., BeckerJ.T.Updated research nosology for HIV-associated neurocognitive disorders. Neurology2007; 69: 1789–1799.
2.
McArthurJ.C., BrewB.J., NathA.Neurological complications of HIV infection. Lancet Neurol2005; 4: 543–555.
3.
VivithanapornP., HeoG., GambleJ.Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology2010; 75: 1150–1158.
4.
PelusoM.J., FerrettiF., PetersonJ.Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS2012; 26: 1765–1774.
5.
LetendreS., Marquie-BeckJ., CapparelliE.Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol2008; 65: 65–70.
6.
CysiqueL.A., VaidaF., LetendreS.Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology2009; 73: 342–348.
7.
SmurzynskiM., WuK., LetendreS.Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS2011; 25: 357–365.
8.
MarraC.M., ZhaoY., CliffordD.B.Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS2009; 23: 1359–1366.
9.
KahouadjiY., DumurgierJ., SellierP.Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Med2012; doi: 10.1111/j.1468-1293.2012.01052.x.
10.
LanoyE., GuiguetM., BentataM.Survival after neuroAIDS: association with antiretroviral CNS penetration-effectiveness score. Neurology2011; 76: 644–651.
11.
LetendreS.L., EllisR., DeutschR.Correlates of time-to-loss-of-viral-response in CSF and plasma in the CHARTER Cohort.17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA.
12.
CiccarelliN., FabbianiM., ColafigliM.Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther2013; doi: 10.3851/IMP2560.
13.
RobertsonK.R., SmurzynskiM., ParsonsT.D.The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS2007; 21: 1915–1921.
14.
SimioniS., CavassiniM., AnnoniJ.M.Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS2010; 24: 1243–1250.
15.
HeatonR.K., CliffordD.B., FranklinD.R.Jr.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology2010; 75: 2087–2096.
